Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs

Inclusion Criteria: * Healthy adults ≥ 19 years of age (on the day of screening) * Body weigth ≥50.0kg, 18.5Kg/(m)\^2 ≤ (BMI) ≤30.0Kg/(m)\^2 * No congenital or chronic diseases and no abnormal signs determined by medical examinations * Not abnormal or not clinical significant lab values * Understand the requirements of the study and voluntarily consent to participate in the study. Exclusion Criteria: * Clinically significant disease with liver, renal, neurologic, respiratory, digestive, endocrine, hemato-oncology, urologic, cardiovascular, musculoskeletal, psychiatric system * Subjects who have hypersensitivity for investigational products * AST or ALT \> 2\*ULN, r-GTP \> 1.5\*ULN, Blood creatinine \> ULN (ULN, Upper Limit of Normal) * SBP ≥ 140 mmHg or\< 90 mmHg, DBP ≥ 90 mmHg or \< 60 mmHg * Subjects who were administered below medications within 30 days (barbiturates, drugs of induced or suppressive drug metabolizing enzyme, etc) * Subjects who previously participated in other clinical trials or bioequivalence Test within 6 months * Subjects with whole blood donation within 2 months or component blood donation within 1 month or blood transfusion within 1 month prior to the first dosing.